TrialPath

Find a study

Match me to a study

228 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

150 studies on the map

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease — Uni of Alabama at Birmingham, BirminghamATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders — Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital, PhoenixA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia — Univ of Alabama Birmingham, BirminghamA Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) — Local Institution - 0106, PhoenixA Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) — University of Colorado Anschutz Medical Campus, AuroraStudy of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V — AKDHC Medical Research ServicesLLC, PhoenixComparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease — Children's of Alabama (MRD-HCT), BirminghamAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants — Research Site, PhoenixA Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants — Local Institution - 0062, MesaA Long-term Follow-up Study in Patients Who Received BEAM-101 — University of Alabama at Birmingham, BirminghamThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — University of Alabama at Birmingham- Site Number : 8400003, BirminghamTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — University of Alabama at Birmingham Cancer Center, BirminghamA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamLupus Landmark Study: A Prospective Registry and Biorepository — University of Alabama at Birmingham, BirminghamThe Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study — University of California, San Francisco, San FranciscoA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) — GSK Investigational Site, AnnistonRESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus — University of California Irvine, OrangeA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus — Sl0044 50058, AvondaleA Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) — Wallace & Lee Center, Beverly HillsA Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus — Research Site, AnnistonPhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). — Pinnacle Research Group Llc, AnnistonA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) — University Of Alabama, BirminghamA Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease — Mayo Clinic, PhoenixA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus — David S Hallegua MD A Professional Corporation, Beverly HillsA Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) — University Of Alabama, BirminghamA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease — Wallace Rheumatic Center, Beverly HillsA Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) — Nkarta Investigational Site, Little RockA Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE — Research Site, San FranciscoVIBRANT: VIB4920 for Active Lupus Nephritis — University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology, La JollaPeer Support for Adolescents and Emerging Adults With Sickle Cell Pain — University of South Alabama Medical Center, MobileA Phase 2/3 Study in Adult and Adolescent Participants With SCD — Smilow Cancer Hospital, New HavenA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases — HonorHealth Research and Innovation Institute, ScottsdaleA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants — Loma Linda University health, Loma LindaSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis — Univ. of California, San Francisco Health Care, OaklandA Study of Obexelimab in Patients With Systemic Lupus Erythematosus — Sierra Pacific Arthritis and Rheumatology Centers, FresnoRecruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease — University of Alabama, Birmingham (UAB), BirminghamAchieving Understanding of the Natural History of Sickle Cell Trait (AUNT) — University of Alabama, BirminghamA Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus — AARA Clinical Research, AvondalePRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis — Purushotham & Akther Kotha MD, Inc., La MesaA Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease — Research Site 4, Redwood CityRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, BirminghamA Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants — GSK Investigational Site, ScottsdaleA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus — Investigative Site, Beverly HillsA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) — Inland Rheumatology Clinical Trials, Inc., UplandTransforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus — University of Alabama Birmingham Hospital, BirminghamA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — University of Alabama Birmingham, BirminghamA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. — Research Site, AnnistonA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease — Dermatology Research Associates - 300204025, Los AngelesA Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) — Pinnacle Research Group /ID# 278677, AnnistonEffects of Stopping Hydroxychloroquine in Elderly Lupus Disease — University of California, Los Angeles, Los AngelesPredictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) — Northwestern University, ChicagoMinimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease — Children's National Health System, Washington D.C.Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial — AARA Clinical Research, GlendaleZinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial — UCSF Benioff Children's Hospital Oakland, OaklandSafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) — UAMS Medical Center, Little RockComparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study — Phoenix VA Health Care System, PhoenixStudy Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants — Research Site, BirminghamStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — Site # 8400006, AtlantaStudy to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN — GSK Investigational Site, BaltimoreA Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants — US06-0, La PalmaSickle Cell Clinical Research and Intervention Program — Children's Hospital of Illinois at OSF-Saint Francis Medical Center, PeoriaGene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesCooperative Assessment of Late Effects for SCD Curative Therapies — Children's National Medical Center, Washington D.C.Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease — University of California Los Angeles, Los AngelesA Socio-ecological Approach for Improving Self-management in Adolescents With SCD — Nemours Children's Health, WilmingtonRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease — Children's Hospital of Colorado, AuroraDelivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease — University of Illinois at Chicago, ChicagoReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders — Yale School of Medicine, New HavenA Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 — Local Institution - 0001, FarmingtonA Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD) — Life Clinical Trials - Colonial Drive - Margate /ID# 276050, MargateEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease — New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New YorkIntegrative Training Program for Pediatric Sickle Cell Pain — Connecticut Children's Medical Center, HartfordApplying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness — Lurie Children's Hospital, ChicagoSCD Stem Cell Mobilization and Apheresis Using Motixafortide — University of Alabama at Birmingham, BirminghamDose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis — Mayo Clinic, RochesterObe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) — State University of New York Upstate Medical Center (SUNY), SyracuseA Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment — Alloy Clinical Research LLC, KissimmeeA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) — Memorial Sloan Kettering at Basking Ridge (Consent only), Basking RidgeIMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy — Hospital for Special Surgery, New YorkClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaMULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease — UH Seidman Cancer Center Adult SCD Clinic or UH Rainbow Babies and Children's Hospital Sickle Cell Anemia Center, ClevelandDescartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders — H01- Children's National Hospital, Washington D.C.Safety of the Herpes Zoster Subunit Vaccine in Lupus — NYU Langone Health, New YorkPrevalence and Clinical Severity of Cutaneous Lupus Erythematosus — Hospital of the University of Pennsylvania, PhiladelphiaStudy of the Role of Genetic Modifiers in Hemoglobinopathies — Boston Children's Hospital, BostonA Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) — Climb Bio Investigative Site #100104, AllenEffect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia — Magee Women's Hospital, PittsburghVerifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease — Cincinnati Children's Hospital Medical Center, CincinnatiSickle Cell Kidney Biorepository — Parkland Memorial Hospital, DallasPhase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders — MD Anderson Cancer Center, HoustonArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesEarly Screening and Treatment of Heart Complication in Sickle Cell Disease — Inova Schar Cancer, FairfaxEffect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease — Methodist Comprehensive Sickle Cell Center, MemphisDapagliflozin in Active Lupus Nephritis — Massachusetts General Hospital, BostonRepository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID) — The Rogosin Institute, New YorkDirect to Patient Minimal Risk Biospecimen and Data Collection Research — Joined Bio, LexingtonUnhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research — Brain Inflammation Collaborative, DelafieldStudy to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaSickle Cell Improvement: Enhancing Care in the Emergency Department — Children's Wisconsin, MilwaukeePeripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisHydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation — Cincinnati Children's Hospital Medical Center, CincinnatiSub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults — Harbor UCLA Medical Center, TorranceSickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders — St. Jude Children's Research Hospital, MemphisVirtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises — University of Maryland Medical Systems, BaltimoreSickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody — Children's National Hospital, Washington D.C.Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX) — St. Jude Children's Research Hospital, MemphisDetermination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling — National Institutes of Health Clinical Center, BethesdaLet's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy — Washington University School of Medicine, St LouisMindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease — University of Illinois Chicago, ChicagoCognitive Remediation Intervention to Prepare for Transition of Care — University of Alabama at Birmingham, BirminghamFLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases — xCures, Los AltosStudy of Panobinostat (LBH589) in Patients With Sickle Cell Disease — Augusta University, AugustaDietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaIntegrative Medicine in Pain Management in Sickle Cell Disease, 2.0 — Indiana University School of Medicine, IndianapolisCollection of Human Biospecimens for Basic and Clinical Research Into Globin Variants — National Institutes of Health Clinical Center, BethesdaCutaneous Hydration Assessment in SCD — UPMC Sickle Cell Clinic, PittsburghPredictors of Pain in Sickle Cell Disease — Duke University Medical Center, DurhamSickleFit Exercise and Nutrition Study — Duke University, DurhamPromoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease — Boston Children's Hospital, BostonSickle Cell Disease Biofluid Chip Technology (SCD BioChip) — University Hospitals Case Medical Center, ClevelandEmpowering Adolescents and Young Adults With Sickle Cell Disease as Partners in Treatment Decision Making (EMPOWER-AYA) — Nemours Children's Hospital, Delaware, WilmingtonAdvancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease — Children's National Hospital, Washington D.C.AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion — New York Medical College, ValhallaCerebral Oxygen Metabolism in Children — Washington University of St. Louis, St LouisMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisPET Imaging of Vaso-Occlusive Crisis (VOC) in SCD — UPMC, PittsburghAlendronate for Osteonecrosis in Adults With Sickle Cell Disease — UC Davis Comprehensive Cancer Center, SacramentoWriting Relaxing Beats in Adolescents Who Have Sickle Cell Disease — Mayo Clinic Division of Nursing, RochesterTocilizumab for Acute Chest Syndrome — University of Chicago, ChicagoSchool Readiness Intervention for Preschool Children With Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisPartial Stem Cell Transplant for Sickle Cell Disease From Matched Donors — National Institutes of Health Clinical Center, BethesdaA Pilot Study on Neuroimaging in SCD: Part of The Boston Consortium to Cure Sickle Cell Disease — Boston Children's Hospital, BostonHematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies — Boston Children's Hospital, BostonHaploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease — City of Hope Medical Center, DuarteTrans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease — Children's Hospital of Atlanta: Eagelston, AtlantaExercise in Child Health — University of California, Irvine, IrvineMetabolic and Hemodynamic Reserve in Pediatric SCA — Washington University in St. Louis, St LouisStudy to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaRelationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET — St. Jude Children's Research Hospital, MemphisProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaGenotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaEarly Life Exposures Among Children With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamSMYLS Multi-site Trial — Medical University of South Carolina, CharlestonStudy of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease — University of Illinois at Chicago, ChicagoSickle Cell, Pain and Mediterranean Diet — University of Illinois Chicago, ChicagoInvestigation of the Genetics of Hematologic Diseases — St. Jude Children's Research Hospital, MemphisA Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease — University of Florida, Gainesville

Showing the 150 nearest — narrow your filters for fewer, closer studies.